Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



ASCO Abstracts: Bristol-Myers Squibb's and Merck's Immuno-Oncology Drugs

The American Society for Clinical Oncology annual meeting starts at the end of the month, but investors will get a peek at the immuno-oncology drugs to be highlighted at the meeting when the abstracts are released at 5 p.m. Eastern on Wednesday.

In the video below, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the PD-1 inhibitors, including Bristol-Myers Squibb's (NYSE: BMY  ) nivolumab and Merck's (NYSE: MRK  ) MK-3475, which are initially being tested in melanoma, but will likely be expanded into other solid tumors.

At ASCO, you can expect to see long-term data for nivolumab in combination with Bristol-Myers Squibb's Yervoy in melanoma patients, and Merck's MK-3475 in patients that have already failed Yervoy. Merck has already applied to the Food and Drug Administration for that indication, so the data should help investors identify any red flags that might disrupt an eventual approval.

Developing drugs is only half the business; good drugmakers have cash to pay investors with dividends
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2956295, ~/Articles/ArticleHandler.aspx, 9/2/2015 11:05:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,141.13 82.78 0.52%
S&P 500 1,920.95 7.10 0.37%
NASD 4,660.53 24.42 0.53%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 10:49 AM
BMY $59.13 Up +0.93 +1.60%
Bristol-Myers Squi… CAPS Rating: ****
MRK $52.37 Down -0.16 -0.30%
Merck & Co., Inc. CAPS Rating: ****